American Century Companies’s Allogene Therapeutics ALLO Stock Holding History

American Century Companies's ALLO Position: Q2 2026 in Review

American Century Companies increased its Allogene Therapeutics (ALLO) stake by 313% in Q2 2026, buying an estimated $345K and bringing the position to 207,404 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

American Century Companies first reported a position in ALLO in Q3 2022 and has held it in 12 quarters since. The position peaked at $558K in Q3 2024. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

• American Century Companies held 207,404 shares of Allogene Therapeutics worth $431K as of Q2 2026.
• American Century Companies bought 157,176 Allogene Therapeutics shares in Q2 2026, an estimated $345K.
• Allogene Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2619 holding.
• American Century Companies first reported a position in Allogene Therapeutics in Q3 2022 and has held it in 12 quarters since.
• American Century Companies's Allogene Therapeutics position peaked at $558K in Q3 2024.
• 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.